

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



廣州白雲山醫葯集團股份有限公司

GUANGZHOU BAIYUNSHAN PHARMACEUTICAL HOLDINGS CO., LTD.

(a joint stock company with limited liability established in the People's Republic of China)

(H Share Stock Code: 00874)

INSIDE INFORMATION APPROVAL GRANTED FOR QUOTATION OF GP CORP. ON NEEQ

This announcement is made by Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd. (the **“Company”**) pursuant to Rule 13.09(2) (a) of the Rules Governing the Listing of Securities (the **“Hong Kong Listing Rules”**) on The Stock Exchange of Hong Kong Limited (the **“Hong Kong Stock Exchange”**) and the Inside Information Provisions (as defined under the Hong Kong Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

APPROVAL GRANTED FOR QUOTATION OF GP CORP. ON NEEQ

Reference is made to the Company's (i) an announcement dated 19 December 2023 and a circular dated 5 January 2024 in relation to the proposed quotation of Guangzhou Pharmaceuticals Co., Ltd (**“GP Corp.”**), a subsidiary of the Company, on the National Equities Exchange and Quotations (the **“NEEQ”**) (the **“Proposed Quotation on NEEQ”**); and (ii) an announcement dated 17 June 2024 in relation to the confirmation from the Hong Kong Stock Exchange that the Company may proceed with the spin-off of GP Corp. by way of quotation on NEEQ pursuant to Practice Note 15 to the Hong Kong Listing Rules (**“PN 15”**) and the grant of a waiver from strict compliance with the applicable requirements in relation to the assured entitlement under paragraph 3(f) of PN 15. GP Corp. has also submitted an application for quotation on NEEQ to the National Equities Exchange and Quotations Co., Ltd. (全國中小企業股份轉讓系統有限責任公司 (**“NEEQ Co., Ltd.”**))), which has been accepted.

The board of directors of the Company (the **“Board”**) hereby announces that on 29 April 2025, GP Corp. received the Approval Letter Regarding the Public Transfer and Quotation of Shares of Guangzhou Pharmaceuticals Co., Ltd. on the National Equities Exchange and Quotations (《關於同意廣州醫葯股份有限公司股票公開轉讓並在全國股轉系統掛牌的函》) issued by NEEQ Co., Ltd., which approved the public transfer and quotation of shares of GP Corp. on NEEQ, with the trading method being collective bidding. As the number of shareholders of GP Corp. at the time of application did not exceed 200, the China Securities Regulatory Commission has exempted GP Corp. from registration in accordance with relevant regulations. Upon quotation, GP Corp. will be governed as a non-listed public company. GP Corp. will complete the necessary procedures for quotation and filing in accordance with the relevant requirements.

After the quotation on NEEQ, GP Corp. will remain a non-wholly owned subsidiary and will continued to be consolidated in the financial statements of the Company. The quotation of GP Corp. on NEEQ will not affect the Company's status as an independently listed company, nor will it have any material impact on the financial position, operating results and sustainable operations of the Company.

GENERAL

The final timetable of the Proposed Quotation on NEEQ remains uncertain. The Company will issue announcements regarding the Proposed Quotation on NEEQ as and when appropriate or required under the Hong Kong Listing Rules and relevant regulatory authorities.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in or investing in the shares or other securities of the Company. Any person who is in doubt about his/her/its position or any action to be taken is recommended to consult his/her/its own professional advisers.

The Board of
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited

Guangzhou, the PRC, 29 April 2025

As at the date of this announcement, the Board comprises Mr. Li Xiaojun, Mr. Yang Jun, Ms. Cheng Ning and Mr. Li Hong as executive Directors, and Mr. Chen Yajin, Mr. Huang Min, Mr. Wong Lung Tak Patrick and Ms. Sun Baoqing as independent non-executive Directors.